98%
921
2 minutes
20
Messenger ribonucleic acid (mRNA), a promising tool in vaccine and therapeutic development, is reliant on intact mRNA delivery into target cells. Given its susceptibility to degradation, ensuring its stability is crucial, necessitating rigorous quality control throughout the product life cycle. This study presents an ion-pair reverse-phase liquid chromatography method that enables rapid and direct mRNA extraction from lipid nanoparticles, facilitated by using a surfactant in the sample preparation. This method, optimized using design of experiments (DoE), allows relative quantification of intact mRNA, mRNA fragments, and mRNA-lipid adducts. Forced degradation studies were used to investigate the impact of mRNA-lipid adducts on protein expression and to identify their chemical structures. The structures, identified by mass spectrometry, suggest reaction mechanisms that differ from those described in the literature so far. Further studies evaluated how formulation parameters such as pH, ionic strength, and buffering species affect mRNA-lipid adduct formation and mRNA fragmentation. A DoE assessed the impact of formulation parameters on mRNA integrity and mRNA-lipid adducts, showing that pH plays the major role. Overall, these findings have significant implications for the design and development of future mRNA-based biopharmaceuticals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12410351 | PMC |
http://dx.doi.org/10.1016/j.omtn.2025.102684 | DOI Listing |
Mol Ther Nucleic Acids
September 2025
Sanofi, 1541 Avenue Marcel Mérieux, 69280 Marcy l'Etoile, France.
Messenger ribonucleic acid (mRNA), a promising tool in vaccine and therapeutic development, is reliant on intact mRNA delivery into target cells. Given its susceptibility to degradation, ensuring its stability is crucial, necessitating rigorous quality control throughout the product life cycle. This study presents an ion-pair reverse-phase liquid chromatography method that enables rapid and direct mRNA extraction from lipid nanoparticles, facilitated by using a surfactant in the sample preparation.
View Article and Find Full Text PDFAnal Chem
February 2025
Waters Corporation, 34 Maple St., Milford, Massachusetts 01757, United States.
Therapeutic drugs and multivalent vaccines based on the delivery of mRNA via lipid nanoparticle (LNP) technologies are expected to dominate the biopharmaceutical industry landscape in the coming years. Many of these innovative therapies include several nucleic acid components (e.g.
View Article and Find Full Text PDFCommun Biol
May 2024
Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-Ku, Sapporo, 060-0812, Japan.
Lipid nanoparticles (LNPs) have emerged as promising platforms for efficient in vivo mRNA delivery owing to advancements in ionizable lipids. However, maintaining the thermostability of mRNA/LNP systems remains challenging. While the importance of only a small amount of lipid impurities on mRNA inactivation is clear, a fundamental solution has not yet been proposed.
View Article and Find Full Text PDF